BMS-986012
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for BMS-986012, covering 2024-03-05 to 2026-06-17. Get the full timeline:
Most recent: Clinical Trial Results: A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer [Phase 2]